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Abstract
Background: The purpose was to validate 90Y PET gradient-based tumor segmentation
in phantoms and to evaluate the impact of the segmentation method on reported
tumor absorbed dose (AD) and biological effective dose (BED) in 90Y microsphere
radioembolization (RE) patients. A semi-automated gradient-based method was applied
to phantoms and patient tumors on the 90Y PET with the initial bounding volume for
gradient detection determined from a registered diagnostic CT or MR; this PET-based
segmentation (PS) was compared with radiologist-defined morphologic segmentation
(MS) on CT or MRI. AD and BED volume histogram metrics (D90, D70, mean) were
calculated using both segmentations and concordance/correlations were investigated.
Spatial concordance was assessed using Dice similarity coefficient (DSC) and mean
distance to agreement (MDA). PS was repeated to assess intra-observer variability.
Results: In phantoms, PS demonstrated high accuracy in lesion volumes (within 15%),
AD metrics (within 11%), high spatial concordance relative to morphologic segmentation
(DSC > 0.86 and MDA < 1.5 mm), and low intra-observer variability (DSC > 0.99, MDA < 0.
2 mm, AD/BED metrics within 2%). For patients (58 lesions), spatial concordance between
PS and MS was degraded compared to in-phantom (average DSC = 0.54, average MDA =
4.8 mm); the average mean tumor AD was 226 ± 153 and 197 ± 138 Gy, respectively for
PS and MS. For patient AD metrics, the best Pearson correlation (r) and concordance
correlation coefficient (ccc) between segmentation methods was found for mean
AD (r = 0.94, ccc = 0.92), but worsened as the metric approached the minimum
dose (for D90, r = 0.77, ccc = 0.69); BED metrics exhibited a similar trend. Patient PS
showed low intra-observer variability (average DSC = 0.81, average MDA = 2.2 mm,
average AD/BED metrics within 3.0%).
Conclusions: 90Y PET gradient-based segmentation led to accurate/robust results
in phantoms, and showed high concordance with MS for reporting mean tumor
AD/BED in patients. However, tumor coverage metrics such as D90 exhibited worse
concordance between segmentation methods, highlighting the need to standardize
segmentation methods when reporting AD/BED metrics from post-therapy 90Y PET.
Estimated differences in reported AD/BED metrics due to segmentation method will be
useful for interpreting RE dosimetry results in the literature including tumor response data.
Keywords: 90Y, Tumor segmentation, 90Y PET, Radioembolization, Dosimetry, Auto-
segmentation, Gradient-based segmentation
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Background
Transarterial radioembolization (RE) with 90Y loaded microspheres is a valuable treat-
ment option for unresectable hepatocellular carcinoma (HCC) and liver metastases [1].
Reported absorbed doses (AD) and biological effective doses (BED) for tumor response
in RE are quite variable [2, 3]. This variability stems from several sources including
microsphere device (glass or resin), tumor type, response metric, and dosimetry model
used. Furthermore, tumor segmentation methodology is not standardized and
end-user-specific details are often lacking in the literature. Tumor segmentation
method, specifically morphological or functional, has been identified as a factor leading
to significant differences in RE dosimetry [3].
Both an estimate of the dose distribution and segmentation is required for reporting
tumor AD/BED metrics. As reviewed by Smits et al. [4], dose distributions in RE have
been estimated from pre-treatment 99mTcMAA SPECT as well as from post-therapy
90Y imaging. It has been documented that MAA distributions are not always concord-
ant or predictive of 90Y microsphere distributions [5], thus for establishing dose–re-
sponse, post-therapy 90Y imaging is preferred. Some RE studies have performed tumor
segmentation on diagnostic contrast computed tomography (CT) or magnetic
resonance imaging (MRI) scans [2, 6–9] while others have used emission-driven
segmentation on FDG PET [10, 11] or 99mTcMAA SPECT [12–14] with a focus on
threshold-based delineation of tumors. A phantom study by Garin et al. [15] showed
that thresholding of MAA SPECT alone had errors from 20 to 210% on average for two
observers; these average errors were reduced to below 10% when guided by CT of the
SPECT/CT. Chiesa et al. [14] compared MAA SPECT thresholding with CT manual
segmentation and found the median absorbed doses for responding lesions to be 521
and 339 Gy, respectively. The scarcity of studies comparing segmentation methods and
the reported large AD differences summarized in [2] demonstrate the need for studies
comparing segmentation methods in RE and their effect on reported AD/BED values.
Although threshold-based segmentation is practical to implement, it is not robust
under different imaging conditions [16]. The optimal threshold level that gives the best
correspondence between the segmented volumes and ground truth has been shown to
be highly dependent on target size, uptake heterogeneity, tumor-to-background ratio
(TBR), and reconstruction method. An alternative emission tomography-based segmen-
tation is the gradient-based method, which determines edges of a target based on
changes in image intensity values at the boundary of the target. A phantom study has
demonstrated higher accuracy with gradient-based segmentation compared with
threshold based segmentation in FDG PET [17]. Gradient-based methods are
semi-automated, require minimal user interaction, and overcome limitations of simple
threshold-based methods. Furthermore, as highlighted in a recent AAPM task group
report on auto-segmentation of PET, a primary advantage of gradient-based methods
over thresholding is that the activity distribution can be non-uniform within the tumor
and background [16]. This is particularly relevant in radioembolization where tumors
may not be fully perfused and microsphere deposition is highly non-uniform due to
clustering of microspheres [18]. A clinical implementation of the gradient-based
method (PETEdge, MIM Inc., Cleveland, OH) has shown high accuracy and improved
reproducibility on FDG PET/CT in lung tumors [19] and solid tumors [20]. Conclu-
sions drawn from segmentation studies with 18F FDG PET may not be applicable to
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90Y PET as microspheres are physically trapped in microvasculature, not metabolized
into cells like FDG. Additionally, 90Y PET images are much noisier than FDG PET im-
ages due to the low positron yield and high fraction of random coincidence events [21].
However, to the best of our knowledge, the gradient-based method or other emission
tomography-based segmentation methods have not been evaluated for 90Y PET.
The primary goal of this work was to quantify differences in 90Y tumor AD/BED esti-
mates when using PET-based segmentation (PS) and morphologic segmentation (MS);
specifically, a commercially available semi-automated gradient-based PS on
post-therapy 90Y PET/CT was compared with manually delineated MS on CT or MRI.
In addition to AD/BED metrics, differences in volume and spatial concordance between
the two methods as well as intra-observer variation of the PS were quantified in both
phantoms and patients.
Methods
90Y PET/CT imaging
90Y PET/CT phantom and patient images were acquired with a Siemens Biograph
mCT (Siemens Molecular Imaging, Hoffman Estates, IL); Phantom and patient PET
data were reconstructed with Siemens 3D-OSEM software using the following parame-
ters that were chosen based on a previous [22] phantom evaluation of contrast, quanti-
fication, and noise: resolution recovery, time-of-flight, 1 iteration 21 subsets, 5-mm
Gaussian post-filter. The PET matrix size was 200 × 200 with a pixel size 4.07 ×
4.07 mm and a slice thickness of 3 mm. The low-dose CT was acquired with tube volt-
age and current of 130 kVp and 80 mAs. The CT matrix size was 512 × 512 with a pixel
size of 0.97 × 0.97 mm and a slice thickness of 2 mm. Identical reconstruction parame-
ters were used for phantoms and patients.
PET Gradient Segmentation
Morphologic 
Segmentation
Rays for initialization 
of gradient-based method
A B C
D E F
18% threshold 
Fig. 1 90Y PET (top) and fused PET/CT (bottom) corresponding to the phantom studies showing MS (green)
and PS (red). Example rays from PETEdge tool are also shown. A threshold of 18% (orange) provided the
best volume estimate (61.8 cc) to the MS in (a) (cold background), while the same 18% threshold
overestimated the sphere volume (102.4 cc) in (b) (warm background). A 32% threshold (not shown) gave
the best volume estimate (61.7 cc) for the MS in (b). Segmentation overlays on the zoomed in PET
component in (a),(b),(c) corresponding to the the fused PET/CT in (d), (e), and (f), respectively
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Phantoms
Three 90Y liver phantom studies were performed (Fig. 1). The first consisted of a
60 cm3 “hot” sphere positioned at the center of a “cold” water-filled phantom. The next
two studies were performed with a liver/lung torso phantom (Data Spectrum Corpor-
ation, Durham, NC, USA) modified to include “tumor” inserts in the 1200 cm3 liver
mimicking conditions following 90Y RE. In one case, a single 60 cm3 “hot” sphere was
positioned in the “warm” liver with a TBR of 5:1, while in the next case two spheres (16
and 8 cm3) and an ellipsoid (29 cm3) were positioned in the “warm” liver TBRs of 5.1,
6.2, and 5.5 for the 8, 16, and 29 cm3 targets, respectively. The volumes 1200, 60, 16,
and 8 cm3 are nominal values; in this work, we take the CT-based segmentation as the
true volume. The total 90Y activity in the liver (3.0 GBq) and acquisition time (25 min)
for the latter experiment was selected to achieve a count/noise-level typical for patient
imaging following RE with glass microspheres.
To illustrate limitations with thresholding, the threshold that best estimated the
60 cm3 sphere’s CT-defined volume in both cold and warm backgrounds was manually
found by adjusting the threshold level. During the threshold procedure, a spherical
region was set to encompass each target with an approximately 1 cm margin as seen
on CT. The purpose of these spherical regions/masks was to bound the threshold vol-
ume to exclude other targets when applying a threshold. The found threshold was then
applied to the sphere in the other background to estimate volume differences.
Patients
Imaging data of 18 patients (21 90Y PET/CT scans as 3 patients had 2 treatments)
treated with 90Y glass microspheres (Therasphere; BTG International Ltd., Ottawa,
Canada) at our institution were retrospectively analyzed. The study was approved by
the University of Michigan Institutional Review Board and all subjects signed an informed
consent for 90Y PET/CT imaging as part of an ongoing research study. Administered
activities were determined following standard clinical protocol, which is based on
Table 1 Summary of analyzed patient and lesion characteristics
Characteristic Patients (radioembolizations) or
Average,median, (range)
HCC 4 (4)a
Cholangiocarcinoma 1 (1)
Liver metastasesb 10 (12)
Total 15 (17c)
Elapsed time between baseline segmentation scan and 90Y PET/CT (days) 57, 49, (0 to 178)
Elapsed time between administration and 90Y PET/CT (min) 139, 144, (44 to 211)
Administered activity (GBq) 2.9, 3.2, (0.6 to 5.8)
Treated volume when determining administered activity (cm3) 1167, 1138, (190 to 2285)
MAA Lung shunt (%) 5.5, 4.4, (1.2 to 17.1)
Lesions per scan (N = 58) 3.4, 3 (1 to 9)
Lesion volume (morphologic) (cm3) 48.4, 11.4 (2.0 to 818)
aAll 4 had cirrhotic livers
bIncludes neuroendocrine, colorectal, pancreatic, melanoma, and adrenal disease
c12 right lobe and 5 left lobe
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recommendations in the package insert. As discussed below, we did not include tumors <
2 cm3, thus Table 1 summarizes characteristics for the remaining 58 lesions in 15 patients
(17 scans) included in our analysis. Post-therapy 90Y PET/CT imaging consisted of
25–30 min continuous bed motion acquisitions localized over the liver performed a few
hours after infusing microspheres.
Morphologically driven segmentation
In phantom studies, volumes of interest (VOI) consisted of manual delineation on axial
slices of the non-contrast CT of the PET/CT by a medical physicist (JM). Lesion out-
lines were well-visualized on CT as evident in Fig. 1.
In patient studies, lesions were usually not well-visualized on the non-contrast CT
from PET/CT, so diagnostic contrast-enhanced CTs or MRIs obtained at baseline
were segmented manually on axial slices (Fig. 2) by a radiologist specializing in hep-
atic malignancies (RK). These images were typically arterial-phase, but not all MRIs
had contrast. Window/level was set to a liver default of 160/40 HU and then adjusted
to maximize contrast. The diagnostic scan was then automatically rigidly registered to
the CT of the 90Y PET/CT, fine manual adjustments were performed, and the lesion
outlines were transformed to the 90Y PET/CT frame of reference (Fig. 2). In some
cases, the radiologist adjusted lesion location manually on the 90Y PET/CT scan when
mis-registration was evident. For example, when a lesion was partially outside the
Fig. 2 Three examples (a–c) showing PET-based (red) and morphologic (green) segmentations on a single
axial slice. Note the scale is different across the three cases and the metrics were evaluated over the full 3D
extent of the VOIs
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liver boundary visible on the CT of PET/CT, the radiologist performed a transla-
tion of the morphologically defined contour to lie within the liver at the appropri-
ate location on the 90Y PET/CT. Lesion location was also adjusted when the
morphologic contour was in close proximity to uptake on the 90Y PET, but did not
coincide. This fine tuning of lesion location compensates for residual registration
errors between the diagnostic morphologic scan and 90Y PET/CT; a single rigid
registration is imperfect because the liver is deformable. In cases (N = 13) where a
narrow window enabled tumor visualization on the non-contrast CT of the 90Y
PET/CT, segmentation was performed directly on the non-contrast CT, thereby re-
ducing registration errors.
A total of 85 tumors were initially segmented on the 21 scans. We excluded
tumors < 2 cm3 because of limited spatial resolution of PET and sensitivity to
mis-registration. An additional 5 tumors were excluded because they showed no PET
uptake (defined as < 5 Gy AD), leaving 58 tumors across 17 scans for analysis.
PET gradient-based segmentation
The commercial gradient-based method (PET Edge, MIM Inc., Cleveland, OH) was
applied to 90Y PET images. It is a semi-automatic method requiring initial condi-
tions determined through minimal user interaction that has been described previ-
ously [19]. Briefly, interaction consists of selecting a plane and then dragging out
rays from the center of the lesion toward the edges (Fig. 1). Six rays extend along
an orthogonal coordinate system as the user drags the ray radially away from the
center. The rays define an ellipsoidal bounding volume for initial gradient detec-
tion. The user is allowed to change the angle of the rays by dragging, and the rays
provide visual feedback showing an estimate of the gradient-determined edge. This
is possible because the spatial gradients are interactively calculated along each ray
and the length of the ray is restricted when a large spatial gradient, indicative of
an edge, is estimated.
The gradient-based segmentations were performed by first localizing to the centroid
of the MS. Although it is possible to union together multiple gradient-based segmenta-
tions to define a volume, we started at the center to avoid having to union volumes to-
gether. Thus, we used a single gradient-based segmentation operation for each lesion
which potentially saves operator time, which is important clinically. The gradient-based
segmentation was initiated from the center of the MS in the plane of maximum mor-
phological extent and the user dragged the mouse so the rays were as close as possible
to the boundary of the MS; we chose to use the gradient-based segmentation tool in
this manner assuming there would be an accompanying morphologic scan where the
tumor would be visible, but not segmented. Our method does not require MS segmen-
tation, but it does require a registered scan showing the full morphological extent,
which the MS segmentation provided for us. However, it should be noted that a CT is
not required for the gradient-based segmentation. Intra-observer variability was
assessed by generating a second gradient-based contour a month later by the same
operator. Gradient-based segmentation on PET was performed by a medical physicist
(JM). First and second gradient-based segmentations will be referred to as PS1 and
PS2, respectively.
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Voxel-level AD and BED
Voxel-level dosimetry was performed with our dose planning nethod (DPM) Monte
Carlo [23] code using the 90Y activity concentration values obtained directly from the
PET image coupled with materials/densities obtained from the CT portion of PET/CT.
The output of DPM is the dose-rate map, which was converted to an AD map account-
ing for 90Y physical decay only, because microspheres are permanently trapped. The
voxel-level BED was calculated from differential absorbed dose volume histogram
(DVH) using the reformulation of the linear quadratic model for radionuclide therapy
[2]: BEDi ¼ Di þ D
2
i
α
β
 ð λλþμÞ , where Di is the absorbed dose at voxel i, λ is the physical
decay constant (0.0108/h), μ is the cell repair constant (0.462/h), and α/β (10 Gy) is the
ratio of radiosensitivity parameters typical for tumors. In addition to mean values,
DVH metrics such as D90 (or BED90), which is the AD (or BED) delivered to 90% of
the tumor volume, were also calculated.
Statistical analysis
Concordance (ccc) and Pearson (r) correlation coefficients were estimated to quantify
agreement and correlation between PS and MS measures (mean AD, D70, D90, mean
BED, BED70, BED90). When estimating correlation, we used the average of the two PS
realizations. We performed two PS segmentations to estimate intra-observer variability;
and to use all data available, we decided to average the measures (mean, D70, D90,
etc.) from the two PS realizations together for the concordance and correlation studies.
To calculate 95% confidence intervals in the presence of possible correlated outcomes
(between lesions within patient), we used a bootstrap approach with sampling at the
patient level. To test for any mean difference in dose metrics between MS and PS re-
gression models, regression models were fit with indicator variable for MS vs PS. To
account for possible correlation between lesions within patient, we included random
patient level intercept terms.
Spatial concordance between PS and MS and between the two PS realizations
was assessed using the Dice similarity coefficient (DSC) and mean distance to
agreement (MDA). DSC is defined as 2(VOI1 ∩ VOI2)/(VOI1 + VOI2), where VOI1
and VOI2 are the volumes from the two segmentations. A value of 1 represents
perfect agreement and 0 indicates no spatial overlap [24]. MDA is the average dis-
tance between the surface of both contours with a value of 0 indicating perfect
agreement [25]. Intra-observer variability between the two PS realizations was also
assessed by calculating DSC and MDA. SAS software (v9.4) and R (v3.4.1) were
used for statistical analysis.
Results
Phantom study
Qualitatively, there was good agreement between MS and PS as the segmentations
nearly overlap (Fig. 1). Quantitative comparisons of the two segmentation methods
and the two realizations of PS are given in Table 2. Figure 1a, b demonstrates the
limitation of a fixed threshold segmentation of the 60 cm3 sphere with different
TBR. A threshold of 18% provided the best volume estimate (61.8 cm3) for the MS
volume (61.6 cm3) of the sphere in a cold background (Fig. 1a). A 32% threshold
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provided the best estimate (61.7 cm3) for the sphere in warm background (Fig. 1b).
Using the 18% threshold with warm background overestimated (102.4 cm3) the MS
volume, while using the 32% threshold in a cold background underestimated (50.8)
the MS volume.
Patient study
Example segmentations
Figure 2 presents examples of MS and PS that include different levels of concordance.
Figure 2a demonstrates a MS with only partial PET uptake; the CT defined contour
was readily seen on contrast CT but it was not clearly visible on CT of PET/CT. There
was concentrated uptake on the 90Y PET, but the MS appeared to not be fully perfused
with microspheres, thus the PS yielded a much smaller volume and spatial concordance
was poor as seen by DSC values indicated in the figure. In Fig. 2b, the large hypodense
core of the lesion is clearly visible on both the diagnostic CT and CT of PET/CT. Al-
though the microspheres were deposited along the lesion’s periphery, the PS was able
to generate a single connected VOI that approximated the MS. Figure 2c shows a
tumor with non-uniform PET uptake, but the PS still agreed well with the MS.
Spatial concordance and comparison of lesion AD/BED results
Boxplots of AD and BED DVH metrics for our population are shown in Fig. 3a, b.
Spatial concordance between PS and MS, as well as PS1 and PS2, are shown in Fig. 3c,
d. Absorbed isodose contours and cumulative DVHs corresponding to the tumors in
Fig. 2 are presented in Fig. 4.
Because Fig. 3 shows low intra-observer variability for PS, when estimating correl-
ation (Figs. 5 and 6, the average of the two PS realizations was used. The AD/BED met-
rics calculated using PS are plotted against the respective quantity calculated from the
Table 2 Summary of phantom results for the two segmentation methods and the two PS realizations
Sphere
8 cm3
Sphere 16 cm3 Ovoid 29 cm3 Sphere 60 cm3
(warm)
Sphere 60 cm3
(cold)
MS volume (cm3) 8.2 15.6 29.8 61.6 61.6
PS volume (cm3)a 9.4, 9.3 17.6, 17.4 28.7, 28.7 56.4, 56.4 61.7, 61.0
bPS vs MS
DSC 0.87 0.86 0.86 0.93 0.97
MDA (mm) 1.20 1.47 1.40 1.20 0.63
ΔDMean (%) − 4.7 − 2.4 1.8 3.5 0.7
ΔD70 (%) − 7.7 − 4.2 3.1 7.4 1.1
ΔD90 (%) − 7.5 0.8 4.5 8.3 3.0
PS1 vs PS2
DSC 0.99 0.99 1.0 0.99 1.0
MDA (mm) 0.15 0.14 0.07 0.15 0.07
ΔDMean (%) 0.3 0.5 0.0 − 0.1 0.6
ΔD70 (%) 0.5 0.9 − 0.1 − 0.1 1.3
ΔD90(%) 0.4 1.5 − 0.1 − 0.4 2.2
aRealization 1 and 2
bPS realization with worst agreement tabulated. Δ represents the relative difference in the reported dose metric with
respect to the MS value
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MS in Fig. 5. PS volumes are plotted against MS volumes in Fig. 6. Excluding three
large volumes (> 200 cm3 on CT) with no central uptake (similar to lesion of Fig. 2b)
changed the fit substantially. Additional details on volume and DVH metrics are tabu-
lated in Tables 3 and 4.
Discussion
The phantom experiments, performed under the clinically realistic noise conditions of
90Y PET, demonstrated high accuracy in lesion volumes (within 15%), AD metrics (within
8%), and high spatial concordance (DSC > 0.86, MDA < 1.5 mm) for PS vs MS (Table 2).
When comparing the two PS realizations for the phantoms, the intra-observer variability
was low (DSC > 0.99, MDA < 0.2 mm, difference in AD metrics < 1.5%).
In patient studies, for tumors < 200 cm3, the PET-based method tended to generate
larger volumes than the corresponding morphologically driven one (Fig. 6). A possible
explanation for the larger PET-based volumes stems from the non-uniformity of the
90Y PET including higher noise levels and respiratory motion leading to spatial spread-
ing of the activity distribution. The AD and BED metrics for PET-based segmentation,
on average, are larger than those corresponding to the MS VOIs (Fig. 3a, b). This
Fig. 3 Boxplots summarizing the tumor AD (a) and BED (b) DVH metrics for MS, PS1, and PS2. Spatial
concordance is summarized in boxplots using DSC (c) and MDA (d). For boxplots, the solid black line
represents the median and dashed line represents the mean. The bottom and top of the box represent the
1st (Q1) and 3rd (Q3) quartile. Whiskers extend to the largest (or smallest) value within 1.5*(Q3 − Q1) + Q3
for largest (Q1 − 1.5 * Q3 − Q1) for smallest)
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appears counterintuitive because the PET-based method in general also had larger vol-
umes. However, the gradient-based method tends to “seek” out or encompass the activ-
ity, thus the preferential localization of activity partially compensates for differences in
volume. In addition, residual registration errors, although minimized, may play a role
in decreasing the activity contained in MS. An example of the larger PS relative to MS
is included as Additional file 1 Supplemental Figure 1. Spatial concordance of the two
A B
C D
E F
Min or
D100
D90
D70
10 Gy
500 Gy
Fig. 4 The absorbed isodose contours (thick lines) with morphologic (thin green lines) and PET-based (thin
red lines) segmentations in (a), (c), and (e) with the corresponding lesion DVHs in (b), (d), and (f),
respectively. These are the same lesions represented in Fig. 2
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methods (Fig. 3c, d) is worse than in the phantom studies; however, 75% of tumors still
had MDA within 5.8 mm, which is less than 1.5 times our PET voxel length. The three
PS1 vs PS2 outliers in Fig. 3c were further investigated and showed large differences in
volume (0.07 vs 14.8 cm3, 1.1 vs 9.7 cm3, 0.4 vs 1.5 cm3). The MDA outlier for PS1 vs
PS2 (Fig. 3d) was also one of these three. The first PS was localized on a relatively intense
uptake within the MS VOI, while the second PS encompassed a volume slightly larger
than the MS. Thus, these were sensitive to initial conditions of the gradient-based seg-
mentation, and additional investigation is needed in the future on this topic. The degrad-
ation of spatial concordance in patient measurements is not surprising considering
Fig. 5 Tumor dose metrics for PET-based vs. morphologic segmentations for AD (a) and BED (b). Mean AD
and BED (green circles), D70 and BED70 (blue triangles), D90 and BED90 (red squares). The dashed line is
the line of equivalence
Fig. 6 Plot comparing PS volumes with MS volumes for 58 tumors. Blue fit line includes all lesions and the
red fit line excludes 3 lesions > 200 cm3. The dashed line is the line of equivalence, and the black crosses
represent our phantom data
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potential biological changes in vasculature and flow dynamics between baseline and
post-therapy imaging, residual registration errors, respiratory motion, and liver deforma-
tions between scans.
For patient AD metrics, the best correlation and concordance between segmentation
methods was found for the mean absorbed dose (r = 0.94, ccc = 0.92) (Fig. 5). As the
AD metric approached the minimum dose (mean ➔ D70 ➔ D90), both the correlation
and concordance worsened (r = 0.77, ccc = 0.70). BED followed a similar trend. A pos-
sible reason for worse concordance with coverage metrics is that as discussed above,
the gradient-based method “seeks” out the activity and localizes and conforms over the
uptake, whereas the shape of the morphologic segmentation is independent of the ac-
tivity distribution. This leads to differences in spatial overlap between contours in the
“lower” dose regions while the “higher” dose regions tended to overlap (Fig. 4a). The
Table 3 Summary of volume and AD/BED metrics for morphologic and PET-based segmentation
MS PS PS - MS [95% CI]
Volume (cm3) 48 ± 130 [2,6,11,30,818] 49 ± 94 [0.3,6,16,47,482] 0.8 [− 6.2, 7.9] p = 0.84
Dmean (Gy) 197 ± 138 [14,92,158,270,546] 227 ± 153 [21,107,192,300,652] 30 [20, 39] p < 0.0001
D70 (Gy) 142 ± 113 [3,72,110,197,452] 180 ± 132 [13,82,145,226,569] 38 [26, 49] p < 0.0001
D90 (Gy) 96 ± 88 [2,37,65,136,370] 140 ± 111 [6,64,115,179,498] 44 [31, 57] p < 0.0001
BEDmean (Gy) 352 ± 325 [14,116,226,469,1280] 415 ± 385 [22,137,282,530,1663] 63 [35, 90] p < 0.0001
BED70 (Gy) 217 ± 218 [3,84,137,285,920] 293 ± 285 [13,97,194,342,1309] 76 [47, 105] p < 0.0001
BED90 (Gy) 135 ± 152 [2,40,75,178,682] 214 ± 217 [6,73,145,252,1064] 79 [50, 107] p < 0.0001
Data in columns 1 and 2 are mean ± stdev [min, 1st quartile, median, 3rd quartile, max]
Table 4 Difference in volume and AD/BED metrics at the lesion level when comparing the two
segmentation methods and the two realizations of PET-based segmentation
PS vs MS PS1 vs PS2
ΔVolume (cm3) 0.8 ± 51 [− 336, − 2, 3, 12, 69] 5 ± 40 [− 78, − 1, 0,4256]
Absorbed Dose
ΔMean (Gy) 30 ± 50 [− 96, 1, 17, 45, 222] − 6 ± 23 [− 103, − 13, − 0,3,37]
ΔD70 (Gy) 38 ± 61 [− 115, 1, 18, 57, 240] − 7 ± 23 [− 85, − 10, − 0,4,40]
ΔD90(Gy) 44 ± 68 [−129, 3, 24, 70, 250] −6 ± 23 [− 84, − 7, 0,3,51]
BED
ΔMean (Gy) 63 ± 142 [− 273, 2, 30, 80, 745] − 14.7 + − 55 [− 266, − 22, − 1, 7, 67]
ΔBED70(Gy) 76 ± 155 [− 308, 2, 29, 113, 733] − 13.8 + − 49 [− 197, − 16, − 1, 6, 75]
ΔBED90 (Gy) 79 ± 152 [− 309, 3, 30, 107, 677] − 11.6 + − 42 [− 170, − 17, 0, 5, 78]
ΔVolume (%) 44 ± 100 [− 85, − 27, 18, 99, 382] 54 ± 253 [− 75, − 10, 1, 25, 1779]
Absorbed Dose
ΔMean (%) 24 ± 36 [− 43, 2, 14, 36, 193] − 2.5 ± 11 [− 39, − 7, − 0, 2, 21]
ΔD70 (%) 49 ± 72 [− 51, 2, 24, 75, 318] − 1.9 ± 16 [− 48, − 9, − 0, 4, 39]
ΔD90(%) 93 ± 150 [− 58, 8, 46, 125, 832] − 0.9 ± 21 [− 52, − 10, 0, 4, 72]
BED
ΔMean (%) 28 ± 42 [− 46, 2, 17, 46, 221] − 3.0 + − 13 [− 45, − 8, − 0,3,25]
ΔBED70(%) 62 ± 85 [− 53, 2, 31, 105, 345] − 2.3 + − 18 [− 54, − 12, − 0,5,42]
ΔBED90(%) 117 ± 183 [− 60, 10, 54, 174, 1026] − 1.2 + − 24 [− 59, − 13, 0,4,89]
The results are listed as mean ± stdev [min, 1st quartile, median, 3rd quartile, max]. The top half of the table represents
absolute differences and the bottom half represents relative differences
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DVHs that are presented also demonstrate this effect; the differences between MS and
PS curves increase for two of the three example cases as one approaches the minimum
dose to the VOI. Another potential reason for differences could be due to respiratory
motion; the 90Y signal will spread out spatially over several respiratory cycles leading to
a larger “low” dose region encompassed by the PS, whereas the MS was based on MRI
or CT from diagnostic studies or the CT component from the free-breathing PET/CT
when lesions were visible on CT.
In terms of intra-observer variability of PS in the patient studies, the average DSC of
0.81 and MDA of 2.2 mm (Fig. 3c, d) are worse than the worst in-phantom measure-
ments; however, 75% of lesions had MDA within 3.3 mm, which is less than a single
PET voxel length. A potential reason for differences includes non-uniform uptake in
less well-defined (no sharp fall off ) geometries in the case of patients when compared
with phantoms. Furthermore, in theory, the PET gradient-based method is robust to
non-uniform distributions, but from a practical point of view, the version studied still
requires initial conditions specified by the user which may not have been reproduced in
cases where the plane of maximum extent was not clear or in cases where the feedback
for edge detection differed because a different ray angle was selected. Such cases can be
seen in PS1 vs PS2 in Fig. 3c, and PS1 vs PS2 in Fig. 3d. Although there was variability
between the PS realizations AD/BED metrics with standard deviations ranging from 11
to 24%, the effect on average was ≤ 3% (Table 4).
There are no studies, to the best of our knowledge, that have evaluated lesion seg-
mentation on post-therapy 90Y PET/CT. However, Chiesa et al. [14] compared thresh-
olding on the pre-therapy 99mTcMAA SPECT with CT-defined volumes for 60 HCC
lesions; they found that the median of the mean AD for tumor response was 522 Gy
for thresholding and 339 Gy for CT-based segmentation. In Fig. 7, we plot the mean
ADs of our PS vs MS alongside Chiesa et al.’s results for threshold-based segmentation
vs MS to demonstrate the differences in concordance achieved in two studies. Although
Fig. 7 Showing our PS vs MS for mean tumor AD alongside 99mTcMAA SPECT threshold-based segmentation
vs MS for mean tumor AD data from Chiesa et al. [14]
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it is difficult to make a direct comparison between Chiesa et al. and our study (HCC vs
multiple diseases, thresholding vs gradient, and 99mTcMAA SPECT vs 90Y PET), the
data suggests that gradient-based segmentation on 90Y PET is more representative of
the morphological delineated tumor volume than the thresholded 99mTcMAA VOI. A
patient example of this is that hypovascular cores were included when using PS (for
example, see Fig. 2b), whereas with thresholding the core would not be included. It is
unclear whether or not to include such cores when reporting tumor dosimetry. How-
ever, it is possible that our method of localizing to the MS and initializing the
gradient-based algorithm’s ray to match the MS may have improved agreement. We be-
lieve that from a practical point of view, this process is very similar to registering a
diagnostic CT or MRI to the 90Y PET/CT and then initializing to the boundary seen on
the fused diagnostic scan that has not been segmented.
One of the advantages of gradient-based segmentation is that it can handle non-uniform
distributions and different TBRs. A phantom example of this is shown in Fig. 1a, b, where
the same sphere in cold and warm background was segmented by morphological,
gradient-based, and thresholding. The optimal threshold of 18% in the cold background over-
estimated the MS in the warm background by approximately 66%, while the optimal thresh-
old of 32% in the warm background underestimated the MS volume in cold background by
approximately 17%. Gradient-based segmentation was within 8.5% of the MS volume. Given
these observations in our phantom data and the strong dependence of the optimal threshold
on TBR, lesion size, and other factors discussed in a recent AAPM report [16] and past
review [26], threshold-based segmentation was not pursued for the patient studies.
Strengths of this study include segmentation on post-therapy 90Y PET/CT potentially
for the first time, validation on clinically realistic phantom studies, using commercially
available clinical segmentation tools, and reporting multiple AD/BED DVH metrics,
which have been used in previous dose-response studies [13, 27]. There are more ad-
vanced segmentation methods for PET than the gradient-based method evaluated here,
but most of these are in the research setting and not available in commercial clinical
software [16]. Finite spatial resolution and noise are inherent limitations to all segmen-
tation methods. Based on our clinically realistic phantom data, the gradient-based
segmentation is highly accurate for our reconstruction parameters, including 5 mm
FWHM post-reconstruction blurring. However, these inherent limitations may hinder
the accurate localization and identification of gradients, and one method of compensat-
ing for these limitations involves deconvolution and bilateral filtering that preserves
edges [16, 17]. Limitations include the small number of patients, the mix of primary
and metastatic hepatic malignancies, and potential impact of mis-registrations. The im-
pact of registration errors was offset by restricting analysis to lesions > 2 cm3. The use
of deformable image registration in the liver was beyond the scope of this study, but it
should be investigated in future work. In addition, inter-observer variability for both
segmentation methods and an estimate of intra-observer variation for MS should be
investigated. It was not the purpose of this work to determine if one method is clinic-
ally superior, but rather to estimate the differences in reporting AD/BED between the
gradient-based and morphological segmentation.
There was not a gold standard in this work. One potential “truth” for clinical segmen-
tation would require excising lesions and liver segments followed by sectioning and
histo/pathology analysis to identify lesion boundaries. Uncertainties including
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registration, deformation, and interval between imaging and excision would still exist,
so this was not pursued. In addition, it is difficult to acquire such data in routine clin-
ical workflows due to extra resources required.
90Y glass microspheres are delivered based on blood flow and become physically
trapped, not metabolized. They are not a biochemical or molecular-based therapy. Seg-
menting lesions solely on activity from the 90Y PET assumes that microspheres came to
rest within a lesion; of course, this may not be true. Consequently, it is prudent to per-
form segmentation with additional information, such as a contrast CT or MR to help
localize the lesions. This is consistent with the PS methodology described in this work.
Correlation between lesion AD and response is beyond the scope of the current study
and will be undertaken in the future. Several studies have shown correlations between
tumor response and mean absorbed dose or mean biological effective dose for 90Y mi-
crospheres [14, 28–30]. There may be additional value to calculate macroscopic
absorbed dose heterogeneity (e.g., incomplete perfusion, necrotic cores). Using αβ ¼ 10
Gy and α = 0.004\Gy [14], we found strong correlation for EUD vs mean absorbed dose
(r > 0.98) and equivalent uniform BED (EUBED) vs mean BED (r > 0.95) for both MS
and PS using 90Y microsphere PET/CT, thus we did not report EUD or EUBED. For
the current absorbed dose levels and value of alpha presented, the EUD and EUBED
can be well approximated by a linear function, due to expansion of exponential. This leads
to the EUD and EUBED calculating the means, which explains the high correlation be-
tween the mean absorbed dose and EUD. The goal of a segmentation method on 90Y
microsphere PET is to report AD/BED DVH metrics that will reliably predict tumor con-
trol and normal tissue complications. This work directly addressed differences in DVH
metrics due to segmentation methods applied to lesions, and the results may aid in the
long-term harmonization of reporting AD/BED metrics across institutions.
Conclusion
Phantom studies showed accurate and robust results for 90Y PET-gradient-based seg-
mentation that is practical to use in the clinic. Quantitative comparisons with morpho-
logically driven lesion segmentations in patient studies showed high concordance for
mean AD and BED while DVH coverage metrics such as D70 and D90 were less con-
cordant between the two segmentation methods. Estimated differences in reported AD/
BED metrics due to segmentation method will be useful for interpreting RE dosimetry
results in the literature including tumor response data. These differences highlight the
need for the RE community to standardize segmentation methods for reporting of
lesion dosimetry on post-therapy 90Y PET.
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